Articles and Videos
InMed’s cannabinol (CBN) formulation for glaucoma – Executive Interview with CEO Eric A. Adams
In this video, InMed Pharmaceuticals CEO Eric A. Adams speaks about the company’s ocular disease program. INM-088 is a cannabinol (CBN) formulation showing potential to...
Source: Edison TV
InMed’s therapeutic development of cannabinol and update on programs – Executive Interview with CEO Eric A. Adams
In this video, InMed Pharmaceuticals' CEO Eric A. Adams speaks about the company’s therapeutic development of cannabinol (CBN), a rare cannabinoid showing potential to treat...
Source: Edison TV
InMed Pharmaceuticals leading the development of cannabinol CBN therapeutics – Executive Interview with CEO Eric A. Adams
InMed Pharmaceuticals is the first company to advance cannabinol (CBN) into clinical trials for therapeutic development. It has begun a Phase 1 clinical trial in...
Source: Edison TV
What is Cannabinol (CBN)? Four things to know about this rare cannabinoid.
What is cannabinol, or CBN? View this infographic to learn four things about cannabinol. Is cannabinol (CBN) psychoactive? How is cannabinol (CBN) different from THC...
InMed Shares Preclinical Data at 2020 EB World Congress
At the EB World Congress in London, UK, InMed's scientific team officially revealed CBN as the active pharmaceutical ingredient (API) in INM-755 while exhibiting preclinical...
Maxim Jacobs Interviews Eric A. Adams about InMed’s Programs Using Cannabinol CBN
In this episode of Edison Talks, Maxim Jacobs, Edison’s director of research for North America, has an in-depth discussion with Eric A. Adams, the CEO...
